实体瘤中检查点抑制剂单药或联合治疗下内分泌免疫相关不良事件的风险与发生率:随机对照试验的荟萃分析
该荟萃分析纳入69项随机对照试验(80份独立报告,42,886例患者),评估实体瘤中免疫检查点抑制剂(ICI)单药或联合治疗下任何级别及3至5级内分泌免疫相关不良事件(eirAEs)的风险与发生率。结果显示,任何级别甲状腺功能减退的风险比为7.81(95%CI 5.68-10.74,P<.0001),发生率为7.64%(95%CI 6.23-9.17,P<.0001);甲状腺功能亢进、垂体炎/垂体功能减退及肾上腺功能不全的风险也显著增加;胰岛素依赖型糖尿病的风险比为1.52(95%CI 1.07-2.18,P=.02),发生率为0.087%(95%CI 0.019-0.189,P=.0006)。ICI联合治疗增加eirAEs风险,尤其是垂体炎/垂体功能减退。
要点
- 任何级别甲状腺功能减退风险比为7.81(95%CI 5.68-10.74,P<.0001),发生率为7.64%(95%CI 6.23-9.17,P<.0001)。
- 甲状腺功能亢进、垂体炎/垂体功能减退及肾上腺功能不全的风险也显著增加。
- 胰岛素依赖型糖尿病风险比为1.52(95%CI 1.07-2.18,P=.02),发生率为0.087%(95%CI 0.019-0.189,P=.0006)。
核心结论
- eirAEs的风险(独立于癌症类型)和发生率在ICI治疗下大幅增加。
- ICI联合治疗增加eirAEs风险,尤其是垂体炎/垂体功能减退。
研究设计与样本
- 通过PubMed/Medline、Embase和Cochrane Library进行电子检索,纳入评估ICI单药或ICI联合治疗下eirAEs的随机对照试验(RCTs)。
- 共纳入69项RCTs(80份独立报告),涉及42,886例患者,使用Stata软件(v17)进行统计分析,并使用Review Manager 5.3评估偏倚风险。
主要发现
- 任何级别甲状腺功能减退的风险比为7.81(95%CI 5.68-10.74,P<.0001),发生率为7.64%(95%CI 6.23-9.17,P<.0001)。
- 甲状腺功能亢进、垂体炎/垂体功能减退及肾上腺功能不全的风险也显著增加。
- 胰岛素依赖型糖尿病的风险比为1.52(95%CI 1.07-2.18,P=.02),发生率为0.087%(95%CI 0.019-0.189,P=.0006)。
- Meta回归显示,ICI联合治疗(纳武利尤单抗联合伊匹木单抗;度伐利尤单抗联合替西木单抗)是任何级别垂体炎/垂体功能减退的独立风险因素。
- ICI药物是肾上腺功能不全风险的独立因素,但癌症类型不是eirAEs的独立风险因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Few meta-analyses on incidence of endocrine immune-related adverse effects (eirAEs) have been published and many trials have been published since. OBJECTIVE: We performed a comprehensive meta-analysis with updated literature to assess risk and incidence of eirAEs of any grade and grade 3 to 5 by immune checkpoint inhibitor (ICI) monotherapy or combination therapy in solid tumors. METHODS: An electronic search using PubMed/Medline, Embase, and the Cochrane Library was performed. Randomized controlled studies (RCTs) assessing eirAEs under ICI monotherapy or ICI combination therapy were selected. Stata software (v17) was used for statistical analyses and risk of bias was evaluated using Review Manager version 5.3. RESULTS: A total of 69 RCTs with 80 independent reports, involving 42 886 patients, were included in the study. Meta-analysis revealed the following pooled estimates for risk ratio and incidence, respectively: for any grade hypothyroidism 7.81 (95% CI, 5.68-10.74, P < .0001) and 7.64% (95% CI, 6.23-9.17, P < .0001); significantly increased also for hyperthyroidism, hypophysitis/hypopituitarism, and adrenal insufficiency; and for insulin-dependent diabetes mellitus 1.52 (95% CI, 1.07-2.18, P = .02), and 0.087% (95% CI, 0.019-0.189, P = .0006), respectively. Meta-regression showed that combination of ICIs (nivolumab plus ipilimumab; durvalumab plus tremelimumab) is an independent risk factor for any grade hypophysitis/hypopituitarism, and that ICI agent is an independent factor of risk for adrenal insufficiency, but that cancer type is not an independent risk factor for eirAEs. CONCLUSION: We showed that risk, independent from cancer type, and incidence of eirAEs are substantially increased with ICI therapy. Combination of ICIs increases risk for eirAEs, especially for hypophysitis/hypopituitarism.
引用
- Vardarli I, Tan S, Brandenburg T, et al. Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2024. PMID: 37967245. doi:10.1210/clinem/dgad670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。